慢性鼻窦炎伴鼻息肉或N-ERD患者生物制剂间转换的疗效与安全性
本研究回顾性分析了本中心接受生物制剂治疗的195例慢性鼻窦炎伴鼻息肉(CRSwNP)或非甾体抗炎药加重呼吸道疾病(N-ERD)患者,其中23例(11.8%)需转换单克隆抗体。多数由奥马珠单抗转换为度普利尤单抗(17/23,73.9%),转换后鼻息肉评分、哮喘控制测试和鼻窦结局测试-22均显著改善。
要点
- 195例中23例(11.8%)需转换生物制剂,多为奥马珠单抗转度普利尤单抗(17/23,73.9%)。
- 17例中9例(52.9%)转换时未设洗脱期。
- 转换后鼻息肉评分、哮喘控制测试及鼻窦结局测试-22均显著改善。
核心结论
- 对于奥马珠单抗治疗反应不足或出现副作用的鼻息肉病患者,转换为度普利尤单抗是有效选择。
- 作者初步结果提示生物制剂间转换可能无需洗脱期,但该发现需进一步研究。
- 其他单克隆抗体转换也显示有希望的结果,但因样本量小需在更大队列中验证。
研究设计与样本
- 回顾性研究,纳入本中心接受生物制剂治疗的CRSwNP或N-ERD患者195例,其中需转换生物制剂者23例(11.8%)。
- 分析指标包括息肉大小变化、生活质量参数、哮喘控制及副作用。
主要发现
- 23例中17例(73.9%)由奥马珠单抗转换为度普利尤单抗,多数因症状控制不足。
- 17例中9例(52.9%)转换时未设洗脱期。
- 转换为度普利尤单抗后,所有患者的鼻息肉评分、哮喘控制测试及鼻窦结局测试-22均显著改善。
- 转换后报告的副作用为干性角结膜炎(4.3%),导致1例患者终止治疗。
- 因样本量有限,其他抗体转换以描述性方式报告。
局限性
- 样本量有限,其他抗体转换以描述性方式报告。
- 作者指出洗脱期可能不必要的初步结果需进一步研究。
- 其他单克隆抗体转换因本研究患者样本小,需在更大队列中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The effectiveness of biologics in chronic rhinosinusitis with nasal polyps (CRSwNP) is well-established. However, real-world experience on the effectiveness of transitioning between two monoclonal antibodies is scarce. Therefore, we aimed to analyze the safety and efficacy of antibody switching in treatment of chronic rhinosinusitis. METHODS: All patients with CRSwNP or nonsteroidal anti-inflammatory drugs-exacerbated respiratory disease (N-ERD) requiring a switch between biologics were retrospectively studied. Analysis included changes in polyp size, quality of life parameters, asthma control, and side effects. RESULTS: Out of 195 patients treated with biologics for CRSwNP or N-ERD in our center, 23 (11.8%) required transition to a different monoclonal antibody. The majority switched from omalizumab to dupilumab (17/23, 73.9%), mostly due to inadequate symptom control. Nine out of these 17 patients (52.9%) were switched without a washout period. All patients showed significant improvement in nasal polyp score, asthma control test and sino-nasal outcome test-22 after changing to dupilumab. Keratoconjunctivitis sicca was the side-effect (4.3%) reported after the switch from omalizumab to dupilumab, which lead to termination of therapy in one patient. Due to limited sample size, other antibody transitions were reported in a descriptive manner. CONCLUSION: The transition to dupilumab is an effective option in patients with inadequate treatment response or side-effects of omalizumab in nasal polyposis. Our preliminary results indicate that a wash-out period may not be necessary when switching between biologics, however, these findings require further investigations. Other monoclonal antibody transitions also show promising results, but warrant validations in larger cohorts due to small patient samples in our study.
引用
- Brkic FF, Liu DT, Klimbacher R, et al. Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD. Rhinology. 2023. PMID: 37515811. doi:10.4193/Rhin22.408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。